Nupsala is proud to announce the launch of the Intibio A2M (Alpha-2-Macroglobulin) processing kit, now available exclusively in the UK through Nupsala. Developed by Intibio, a leading Belgium biologics company, this innovative kit introduces several technical modifications and enhanced levels of essential proteins and growth factors, this provides equine veterinarians with a valuable new option for A2M processing.

Our new INTIBIO A2MG kit provides an evidence based orthobiologic solution based on a patented technology using unique filters. The INTIBIO A2MG kit results in the highest A2MG levels (and volume), total protein amounts and growth factor levels in comparison to commercially available alternatives.

To further support veterinary professionals, Nupsala now also offers its own centrifuge system. This system is designed to work seamlessly with the Intibio A2MG kit and other A2M products, offering vets a complete and flexible solution for A2M processing.

Nupsala remains firmly committed to the principles of professional ethics, product neutrality, and unbiased clinical choice. We believe that veterinarians should be empowered to make informed decisions based on value, performance, and patient outcomes.

Prof. Dr. Jan H. Spaas (CEO of Intibio):

“We are excited to announce our strategic partnership with Nupsala, a leading veterinary player in the UK, to bring our novel orthobiologics kit to veterinary clinicians across the region. This collaboration marks a significant milestone in our mission to advance veterinary care by expanding access to innovative, evidence-based solutions. The partnership combines our cutting-edge orthobiologics technology with Nupsala’s scientific approach, deep market knowledge and established distribution network, ensuring that veterinarians in the UK are equipped with high-quality tools to support patient outcomes. We look forward to a successful collaboration that drives innovation, improves care, and supports the growing demand for biologically driven orthopedic therapies.”

Greg McGarrell, CEO of Nupsala, commented:

“At Nupsala, we are committed to supporting innovation that genuinely advances equine health. Our new collaboration with INTIBIO reflects this commitment and brings together the shared expertise, integrity, and forward-thinking approach of both companies. The Intibio A2M processing kit represents the next evolutionary step in equine orthobiological therapies—offering veterinarians a high-quality, accessible solution grounded in science. We’re proud to partner with a company that values collaboration as much as we do, and we look forward to what this means for the future of equine care”

The Intibio A2M kit is compatible with existing centrifuge systems, and comparative studies are available upon request.

Nupsala remains dedicated to supporting equine veterinarians with ethical, innovative, and effective solutions — because choice drives progress.